Boston Scientific stock remains under pressure as Q4 outlook weakens

Published on 11/06/2026 at 17:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Boston Scientific stock was quoted at 38.86 euros on Lang & Schwarz on Friday. A weaker fourth-quarter outlook keeps execution in focus.

Outlook and pipeline remain in focus

Boston Scientific expects fourth-quarter reported and organic sales to decline by 1 percent to 3 percent year over year.
Product clearances, the Elite AF trial and a Heartflow collaboration support the longer-term pipeline.
Full-year 2026 adjusted earnings-per-share guidance stands at 3.16 to 3.18 US dollars.

Boston Scientific, US1011371077, Illustration mit AI erstellt.

Boston Scientific stock was quoted at 38.86 euros on Lang & Schwarz at 17:00 CET on Friday, November 6, 2026.

Boston Scientific reported its third-quarter results on October 28, with sales rising 1.5 percent year over year to 5.138 billion US dollars. The update also pointed to weaker near-term expectations after operational disruption affected the quarter.

Fourth-quarter pressure remains

Management expects reported and organic sales to decline between 1 percent and 3 percent in the fourth quarter from the prior-year period. Full-year 2026 reported sales growth is expected at 4.25 percent, while organic growth is projected at 3.75 percent. Adjusted earnings per share guidance stands at 3.16 to 3.18 US dollars for the year and 0.77 to 0.79 US dollars for the fourth quarter.

The outlook leaves execution and recovery as the immediate investor focus. The company continues to build its longer-term position through new products, clinical development and technology partnerships.

Pipeline provides longer-term support

Boston Scientific received FDA 510(k) clearance for the Navigator Flex ureteral access sheath, the LithoVue Elite single-use ureteroscope with temperature sensing and expanded sizes of the SEISMIQ intravascular lithotripsy catheter. It also began enrollment in the Elite AF trial for its next-generation WATCHMAN platform.

A strategic collaboration with Heartflow is intended to advance AI-powered, CT-guided planning for percutaneous coronary intervention. Category I CPT codes for selected renal denervation and implantable tibial nerve stimulation devices are scheduled to take effect in January 2028.

Investors will watch whether these product and clinical milestones can support growth while the company works through the weaker fourth-quarter outlook. The real-time quote of Boston Scientific stock provides the latest trading reference.

The S&P 500 provides the relevant market backdrop for Boston Scientific stock.

More news and analyses on Boston Scientific stock